Reliv International Inc (RELV) is expected to report for 4Q. Rubicon Technology Inc (RBCN) is expected to report for 4Q. Ryvyl Inc (RVYL) is expected to report $-0.33 for 4Q. SouthGobi Resources Ltd ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...

Kennedy has touted the benefits of an unconventional measles treatment including the steroid budesonide, the antibiotic ...

Equities researchers at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for shares of HLS Therapeutics ...

So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Aquestive Therapeutics is expected to lag the wider industry.

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

A symmetrical triangle pattern has formed in the chart of Autolus Therapeutics PLC (NASDAQ:AUTL). The stock is expected to ...

Cintas Corporation CTAS shares jumped over 8% on Wednesday after the company posted better-than-expected third-quarter ...

Shares of NASDAQ SMMT opened at $19.75 on ... price is $20.06. The firm has a market capitalization of $14.57 billion, a PE ratio of -70.53 and a beta of -1.04. Summit Therapeutics (NASDAQ:SMMT ...

BofA analyst Tim Anderson raised the firm’s price target on Aardvark Therapeutics (AARD) to $26 from $22 and keeps a Buy rating on the shares ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intensity Therapeutics, Inc. (INTS – Research Report) and Stoke Therapeutics (STOK – Research ...

SAN JOSE, Calif. - Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $81 million, has announced promising preclinical study ...